This website is intended for healthcare professionals only

Newsletter      
Hospital Healthcare Europe
HOPE LOGO
Hospital Healthcare Europe

Share this article

Follow by Email
Facebook
Twitter

DePuy Synthes and Ethicon showcase intraoperative solutions aimed at reducing surgical site infections


6 June, 2017  

DePuy Synthes and Ethicon, both businesses of Johnson & Johnson Medical Devices, joined forces at the 18th European Federation of National Associations of Orthopaedics and Traumatology (EFORT) Congress in Vienna, to showcase a range of knee and hip procedural solutions to support health systems in meeting their Triple Aim goals of reducing costs, enhancing patient outcomes and increasing patient satisfaction by reducing the rate of surgical site infections (SSIs).

SSIs are a major health concern that can have a significant impact on orthopaedic patients, with infection decreasing patient quality of life and representing a major clinical and economic burden in knee and hip arthroplasty.1,2

We see a tremendous opportunity to help improve orthopaedic patient outcomes through cross-portfolio procedural offerings” said Michelle Brennan, Company Group Chair, Johnson & Johnson Medical Devices EMEA. “Our range of complementary technologies seek to address the need for standardisation and efficiencies in the operating room, while mitigating the threat of surgical site infections which can be an unexpected and traumatic event during a patient’s journey to recovery”.

The businesses are proud to be exhibiting their suite of procedural solutions during the congress, including:

  • From DePuy Synthes; the ATTUNE® Knee System, designed to improve functional outcomes for patients, performance for surgeons, and efficiency for providers;and the CORAIL® PINNACLE® Total Hip System, one of the most widely used and clinically successful constructs in total hip replacement.3-8
  • From Ethicon; wound closure products including the DERMABOND® PRINEO® Skin Closure System which provides a flexible microbial barrier with 99% protection in vitro for 72 hours against organisms commonly responsible for SSIs,9 complimented by Ethicon’s range of Plus Sutures, including the STRATAFIX™ Plus Knotless Tissue Control Device – with Ethicon Plus antibacterial triclosan coating. Plus Sutures have been proven in vitro to inhibit colonisation of the suture by bacteria associated with SSIs.10,11,13,14

Johnson & Johnson Medical Devices remains committed to the fight against SSIs for patients and healthcare systems alike.  Infection prevention is rooted in the company’s heritage and its range of knee and hip procedural solutions affords orthopaedic surgeons a collection of complementary technologies across the entire patient pathway, from exposure to closure.

References

  1. Patel H, Khoury H, Girgenti D, Welner S, Yu H (2016) Burden of Surgical Site Infections Associated with Arthroplasty and the Contribution of Staphylococcus aureus. Surg Infect (Larchmt) 17 (1): 78-88
  2. Whitehouse JD, Friedman ND, Kirkland KB, Richardson WJ, Sexton DJ (2002) The impact of surgical-site infections following orthopedic surgery at a community hospital and a university hospital: adverse quality of life, excess length of stay, and extra cost. Infect Control Hosp Epidemiol 23 (4): 183-189
  3. CORAIL PINNACLE Sales Data; 1986-2016; Data on file DePuy Synthes.
  4. Orthopaedic Data Evaluation Panel. ODEP product ratings. Latest ODEP ratings can be found at www.odep.org.uk [Accessed 01/10/2016].
  5. Hallan G, Lie SA, Furnes O, Engesaeter LB, Vollset SE, Havelin L. Medium and long-term performance of 11 516 uncemented primary femoral stems from the Norwegian arthroplasty register. J. Bone Joint Surg. 2007;89-B:1574-1580.
  6. Chatelet J-C. Survivorship in 120 consecutive cases at 12 years. Rev Chir Orthop Reparatrice Appar Mot. 2004;90(7):628-635.
  7. Bedard N, Callaghan J, Stefl M, Williams T, Liu S, Goetz D. Fixation and Wear with Contemporary Acetabular Components and Cross-Linked Polyethylene at 10-Year Follow- Up. Journal of Arthroplasty. 2014; 29: 1961-1969.
  8. National Joint Registry for England, Wales, Northern Ireland and the Isle of Man, 13th Annual Report, 2016. Table 3.9. Available from www.njrreports.org.uk
  9. Ethicon Inc, 06TR071 [Study Report for in vitro evaluation of microbial barrier properties of DERMABOND™ ProTape ], December 2006, Data on File.
  10. Storch ML, et al. Experimental efficacy study of coated VICRYL plus antibacterial suture in guinea pigs challenged with Staphylococcus aureus. Surg Infect (Larchmt) 2004;5:281–8
  11. Fleck T, et al, Triclosan-coated sutures for the reduction of sternal wound infections: economic considerations, Ann Thorac Surg. 2007; 84: 232–236
  12. Leaper DJ, et al. Surgical site infection – a European perspective of incidence and economic burden. Int Wound J 2004;1:247–73
  13. Ming X, Rothenburger S, Nichols MM. In vivo and invitro antibacterial efficacy of PDS Plus (polidioxanone with triclosan) suture. Surg Infect. 2008;9(4):451-457
  14. Ming X, Rothenburger S, Yang D. In vitro antibacterial efficacy of Monocryl Plus Antibacterial Suture (poligelcaprone 25 with triclosan). Surg Infect. 2007;8(2):201-207